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The key principles of the 1999 guidelines that pertain
to this guidance are:
 The safety of the patient and of the wider community
is paramount.
 Good assessment procedures and mechanisms to
prevent the diversion of prescribed medication will
promote safety and improve patient outcome.
 The care and treatment of drug users is a multi-
disciplinary and multi-agency activity. Shared care is
a rational model for service delivery within which
patients prescribed buprenorphine can be managed.
 Patient involvement in their treatment is essential.
 Patient education about treatment effects is important.
 Clinicians should not undertake specific interventions
beyond their level of competence and confidence.
Training and professional development should underpin
clinical practice.
The production of this guidance was stimulated by the
needs of primary care practitioners themselves, leading to
requests for such guidance at the Royal College of General
Practitioners (RCGP) 6th National Conference ‘Management
of Drug Users in General Practice’ in May 2001.
Since the publication of the Clinical Guidelines there has
been the development of a new type of general practitioner,
defined as the GP with a Special Interest (GPwSI). The
GPwSI can play an important role in the implementation
of this guidance as can the Practitioner with a Special
Interest (PwSI), which includes nurses and pharmacists.
Who is the guidance for?
The guidance is aimed at clinicians involved in the care
of drug users and has been developed specifically to
support the use of buprenorphine in primary care. It is
anticipated that GPs, nurse specialists and pharmacists
will find the guidance particularly relevant.
Evidence-based guidance
This guidance draws on the international research literature.
It is recognised that this is a developing evidence base,
and that this update incorporates new evidence since
the guidance was first published in 2003. Further updates
will also be required as there are some areas of clinical
practice with buprenorphine for which, up to now, there
is limited or no direct evidence available.
To address these evidence gaps, this document draws
upon the clinical experience of experts in the field from
primary and secondary care, involving discussion with
international2 and national colleagues3. It also draws
upon parallels from conventional methadone practice.
1. Rationale for use of buprenorphine
There is a growing body of evidence that treatment for
opioid dependence can be effective4. Methadone
substitute prescribing is one well-established treatment
modality and is supported by a substantial body of
research literature and clinical practice5. However,
methadone is not suitable for, or popular with, all opioid
users seeking treatment. The provision of a flexible menu
of effective treatment options, and some degree of choice
for those seeking treatment6, is likely to optimise the
outcomes and process of treatment of opioid dependence.
Buprenorphine is an effective, safe medication for use in
the treatment of opioid dependence and is a valuable
addition to the formulary of medications for treating opioid
dependence7. It was licensed for use in opioid
dependency in the UK in 1999. It has been used in other
parts of the world (e.g. France, Australia) for longer.
It is a partial opioid agonist, appears safer in overdose
than methadone and may have an easier withdrawal
phase. It can be used for maintenance or detoxification.
Background
This guidance has been produced to aid medical practitioners in the use of buprenorphine
as a substitute medication for opioid dependence for maintenance and detoxification.
It should be read in conjunction with ‘Drug Misuse and Dependence: Guidelines on Clinical
Management’ issued by the UK Departments of Health in 19991.
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A number of randomised trials suggest that buprenorphine
exhibits comparable efficacy to methadone as substitute
maintenance medication when used in equivalent doses8.
Others show buprenorphine given in flexible doses
appeared statistically significantly less effective than
methadone in retaining patients in treatment but may
suppress heroin use better9 10. It is likely that there will
be some patients who respond better to methadone
maintenance and others to buprenorphine maintenance,
with each medication having potential advantages and
disadvantages.
There are relatively few controlled trials of using
buprenorphine as a detoxification agent11. A Cochrane
review of the available information, which requires updating,
showed that buprenorphine is able to relieve the signs
and symptoms of withdrawal from heroin and methadone,
but further investigation is required12. Evidence regarding
buprenorphine efficacy compared to methadone as a
detoxification agent is limited but it appears to be more
effective than symptomatic medications such as alpha-
adrenergic agonists (e.g. lofexidine or clonidine) in
managing detoxification from heroin or methadone.
2. Clinical pharmacology
Buprenorphine is a semi-synthetic opioid derived from
the morphine alkaloid thebaine. It is a mixed agonist-
antagonist and its primary action is as a partial opiate
agonist. An understanding of its pharmacology will help
guide its clinical use7.
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Buprenorphine:
 has low intrinsic agonist activity, only partially
activating mu opioid receptors, and consequently
high buprenorphine doses produce a milder, less
euphoric and less sedating effect than high doses
of other opioids such as heroin, methadone or
morphine. However, it exerts sufficient opiate
effects to prevent or alleviate opioid withdrawal
including craving.
 has a high affinity for mu receptors and binds
more tightly than heroin, methadone or morphine.
It reduces the impact of additional opioid use
(when prescribed in doses greater than 8 mg)
by preventing the receptors being occupied by
these additional opioids.
 binds strongly to kappa opioid receptors where
it acts as an opioid antagonist.
Buprenorphine therefore produces opioid responses
while also reducing the effect of additional heroin,
methadone or morphine.
Box 1
3
Figure 1   Opioid effect with dose of different drugs
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4. Choosing between buprenorphine
and methadone
There has been a recent Cochrane systematic review for
maintenance9. This Cochrane review identified thirteen
randomised controlled trials (RCTs) on maintenance,
all but one of which were double-blind. They evaluated
the effects of buprenorphine maintenance against placebo
and methadone maintenance in retaining patients in
treatment and in suppressing illicit drug use.
Cochrane meta-analysis found the following results:
 At average / common methadone doses currently
used in the UK (30 to 60 mg) buprenorphine can
achieve broadly comparable outcomes. Specifically,
buprenorphine given in flexible doses appeared
statistically significantly less effective than methadone
in retaining patients in treatment, but there was a trend
(not significant) for less heroin use in buprenorphine
groups compared with methadone groups.
 Optimal doses of methadone (e.g. 80  to 120 mg) are
still the gold standard for maintenance.
 The efficacy of high dose buprenorphine (16 to 32 mg)
compared with higher dose methadone (80 to 120 mg)
had not been examined in comparative studies.
The reviewers conclude that buprenorphine is an effective
intervention for use in the maintenance treatment of
heroin dependence, but it is not more effective than
methadone at adequate dosages. Also, buprenorphine
is not significantly different from methadone in the impact
on other substance use (e.g. cocaine, benzodiazepines,
alcohol).
With similar outcomes, the choice between methadone
and buprenorphine should be informed by other factors14.
There is limited evidence of the superiority of either
medication for particular subgroups, and the decision as
to which medication to use should be made in consultation
with each patient after consideration of the relative merits
of each medication.
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Buprenorphine sublingual tablets are licensed for treating
opioid dependence in the UK. They contain buprenorphine
hydrochloride and are available in 400 micrograms
(or 0.4 mg), 2 mg and 8 mg strengths. The tablets are
administered sublingually because it has poor oral
bioavailability (inactivated by gastric acid and a high
first pass metabolism).
Relevant properties
 Time to peak concentration
90 to 150 minutes after sublingual administration
 Time for peak clinical effects
1 to 4 hours post dose
 Duration of action
Related to dose:
 Low doses e.g. 2 to 4 mg exerts clinical effects
for up to 12 hours
 Higher doses e.g. 16 to 32 mg can exert effects
for up to 48 to 72 hours
 Metabolism
Principally in the liver via two hepatic pathways:
glucuronide conjugation and N-dealkylation by the
CP450 enzyme system
 Excretion
Principally in the faeces and urine
 Elimination half-life
Between 20 and 37 hours
 Blockade dose (dose where effects of additional
opioids are markedly reduced)
Maximal above 12 to 16 mg daily
 Maintenance doses
Between 8 to 32 mg daily
 Equivalence
Direct equivalence is difficult to estimate and is not a
linear relationship. When comparing the efficacy of
maintenance doses, 12 to 16 mg buprenorphine
(sublingual tablets) is approximately as effective as
50 to 80 mg methadone in reducing heroin use and
retaining patients in treatment12. It is difficult to
compare doses above 80 mg of methadone and
above 16 mg of buprenorphine because of their 
different effects.
 Easily soluble
As buprenorphine is easily soluble there is a risk that
it can be dissolved and injected. Consumption of the
drug should be supervised to begin with to limit this
risk. Injecting buprenorphine tablets can be associated
with venous damage, pain on injecting, infections, risk
of blood borne viruses and toxic hepatitis.
Effects and unwanted effects
Most unwanted effects of buprenorphine are similar to
those associated with other opioids, including constipation,
headaches (common with buprenorphine), sleeplessness,
sickness and sweating. In addition many patients complain
of a bitter taste. As with other opiates, side effects vary
from individual to individual, but are usually most prominent
in the first few days of treatment.
Subjectively, many patients on buprenorphine treatment
often report a ‘clear head’ response quite different to the
‘clouding’ associated with heroin or methadone use. Some
patients find this ‘clarity’ uncomfortable whilst others
may value it. This subjective experience may be a factor
that influences patient choice.
3. Indications, contraindications and
precautions for use in primary care
An assessment is essential to determine suitability for
treatment. This should include urine drug testing to
ascertain the presence of opioids. Patients entering
treatment should have: liver function tests (LFTs) and
screening for blood borne viruses (HIV and hepatitis A,
B and C), although initiation of treatment should not be
unnecessarily delayed whilst waiting for the results.
Its optimal use, like other medications, will depend on
adequate dosing and the concurrent delivery of non-
pharmacological interventions that directly and indirectly
address the underlying disorder of opioid dependency7.
More work needs to be undertaken to ascertain which
people are best suited to buprenorphine treatment.
It may well be suited for treatment in primary care, outside
more traditional opioid treatment delivery systems7.
Indications for use: Buprenorphine treatment should
be considered for the following populations:
 Opioid dependent
 Informed consent to treatment with buprenorphine
Contraindications: Buprenorphine should not be used
with the following populations:
 Allergic or sensitive to buprenorphine
 Under 16 years (except on the advice of a specialist)
 The licence for buprenorphine does not cover breast-
feeding mothers (see Box 2 re pregnancy).
Pregnancy
Pregnancy is not a contraindication under the UK
MHRA licence, rather it is a special warning.
Trials suggest that it may be useful in pregnancy
but currently there is as yet insufficient safety data
to recommend its use. It has a similar incidence,
compared to methadone, of neonatal abstinence
syndrome but this tends to be less severe and needs
less and shorter treatment. A pregnant patient on
buprenorphine should be referred to a specialist
and told that she can continue with the current
treatment while at the same time being made aware
of the facts13. Recommend that the patient has
given informed consent and it is documented in
their notes.
Box 2
Precautions:
Caution should be exercised in prescribing
buprenorphine for the following patients:
1. Concurrent use of other sedating drugs
or medications. As with methadone,
buprenorphine can be associated with sedation,
respiratory depression and coma when used in
conjunction with central nervous system (CNS)
depressants, such as alcohol, benzodiazepines,
barbiturates, neuroleptics, and tricyclic anti-
depressants.
2. Patients in methadone treatment at doses
of greater than 30 mg. Transferring to
buprenorphine is likely to be associated with
precipitated withdrawal (see Box 4) and should
only be attempted after consultation with a
specialist or experienced prescriber.
3. Medical conditions complicating opioid use.
As with other opioids (including methadone),
buprenorphine should be used cautiously in
individuals with recent head injury, acute
abdominal conditions, or with severe respiratory,
hepatic or renal disease.
4. Patients suffering with chronic pain – for which
additional opioid analgesia is frequently required.
5. People with severe mental illness, with limited
capacity to provide informed consent.
Box 3
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The principles of safe induction with buprenorphine are:
 Delay the first dose of buprenorphine until the patient
is experiencing features of opioid withdrawal (this
typically means at least 8 hours after last heroin use,
or 24 to 48 hours after last methadone use).
 Commence with an initial buprenorphine dose of
between 4 and 8 mg.
 Increase the buprenorphine dose on subsequent days,
or later the same day if facilities are available, according
to clinical response.
 Rapidly titrate the buprenorphine dose on subsequent
days according to clinical response by 2 to 4 mg
(although dose increases of up to 8 mg are generally
safe).
 Ensure frequent review of the patient and supervised
consumption where available.
 Provide a full explanation to the patient and their
partner/ carer, if appropriate, supported by written
information to include: the properties of the drug, how
it works, the induction period and the possible side
effects and provide patient leaflet (see Appendix 1).
 Ensure patients understand that most people take
several days to stabilise on their medication, particularly
if transferring from methadone (where it can take
1 to 2 weeks for patients to stabilise). Precipitated
withdrawal should also be explained (see Box 4).
 Offer to see the patient yourself (or a team member)
before the next appointment if required and coordinate
with the pharmacist.
Transition to buprenorphine from heroin or low dose
methadone (30 mg or below) can usually be accomplished
with minimal complications, although restlessness,
insomnia, headache, diarrhoea and other mild opioid
withdrawal-like symptoms are not uncommon in the first
1 to 3 days. Lofexidine may be helpful with these
unpleasant effects. It can be used for 1 to 2 days two
tablets four times a day. Some patients transferring from
methadone to buprenorphine find it difficult to stabilise
and feel uncomfortable on buprenorphine for 1 or
2 weeks. Steady state in blood concentration levels
is reached after about 5 to 8 days. Advice about
sleep hygiene should be given.
Dispensing and supervision
The Clinical Guidelines1 recommend that buprenorphine
is dispensed daily during induction and that consumption,
if possible, is supervised by the pharmacist for a period
of time which may be, depending on the patient for at
least the first 3 months.
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There appears to be increasing consensus amongst
clinicians experienced in choosing both buprenorphine
and methadone that:
 Buprenorphine may be better suited to those who
wish to cease using heroin completely, as the blockade
effects of even moderate dose buprenorphine interfere
with the subjective effects of additional heroin use. In
contrast, whilst high dose methadone treatment is
also well suited to those who wish to stop using heroin,
those patients who wish to continue to use heroin
may prefer low dose methadone treatment.
 Withdrawal from buprenorphine appears to be easier
than from methadone, and as such may be preferred
for those considering a detoxification program.
 The transition from buprenorphine to naltrexone can
be accomplished much earlier than the transition from
methadone to naltrexone, and consequently, those
considering naltrexone treatment after detoxification
may be better suited to buprenorphine.
 Buprenorphine is less affected by interactions with
hepatic enzyme inducers/inhibitors (anti-convulsants,
rifampicin, ribavirin).
 Buprenorphine is less sedating than methadone.
This may be positive or negative for different patients.
 Using buprenorphine alone is safer in overdose.
Patients who are not responding well to adequate doses
of methadone or buprenorphine, or who are experiencing
persistent unwanted effects or difficulties with their
medication may benefit from transferring to the other
medication or referral to a specialist practitioner for review.
It should be emphasised that patients doing well on either
methadone or buprenorphine should remain on that
medication.
5. Choosing between maintenance 
and detoxification
Buprenorphine can be used as a maintenance intervention
or as a detoxification agent.
Maintenance is suitable for patients who want to stop
using illicit opioids but are unable to achieve abstinence
from all opioids at present. Prescribing is long-term at
effective doses individualised for each patient. The goal
is harm reduction and stabilisation of life-style. When
comparing detoxification and maintenance treatment
with methadone, outcomes are considerably better with
long-term maintenance treatment16. There is some
evidence to suggest this is also true with buprenorphine17.
Detoxification can be attempted with patients who wish
to detoxify from all opioids. There is a high relapse rate
to heroin use unless detoxification is combined with
psychosocial interventions. As such, detoxification should
not normally be seen as a stand-alone treatment modality
and should not be imposed.
6. Starting buprenorphine – induction
The purpose of induction is to safely establish the patient
as quickly as possible on a dose of buprenorphine that
prevents opioid withdrawal, reduces the need to take
additional illicit opioids and keeps side effects to a
minimum. It is usual to start on a low dose and increase
rapidly, over the course of a few days, until a stabilising
dose (e.g. 16 mg) is reached. Induction can be effected
for patients using heroin or methadone. The key to
understanding buprenorphine induction is the
phenomenon of precipitated withdrawal (see Box 4).
Efficacy of BPN maintenance treatment
For heroin use and treatment retention in RCTs
High dose MMT (>80 mg)
better than
Medium dose MMT (40 to 80 mg)
= Medium dose BMT (8 to 12 mg)
better than
Low dose MMT (<40 mg)
= Low dose BMT (<8 mg)
Note: No RCTs of high dose BPN (≥16 mg)
to methadone
MMT = Methadone maintenance treatment
BMT = Buprenorphine maintenance treatment
Figure 215
Precipitated withdrawal
This form of opiate withdrawal can occur in someone
commencing buprenorphine who has recently used
heroin (less than 8 hours previously) or methadone
(less than 24 hours previously). It is caused by the
high affinity of buprenorphine displacing other opioids
(e.g. methadone, heroin) from opioid receptors, but
having less opioid activity (partial agonist). This rapid
reduction in opiate effects can be experienced as
precipitated withdrawal, typically occurring within
1 to 3 hours after the first buprenorphine dose,
peaking in severity over the first 3 to 6 hours and
then generally subsiding. If it occurs, reassure the
patient and carer and offer symptomatic treatment
such as lofexidine (e.g. 400 to 600 mcg 8 hourly
for 1 to 2 days), as appropriate, if withdrawal
symptoms are severe. Do not prescribe more
buprenorphine until the opiate withdrawal
symptoms have settled.
Box 4
Figure 3
Pathways into and out of buprenorphine treatment
Naltrexone
protected
No ongoing
pharmacotherapy
Ongoing
buprenorphine
maintenance
Transfer to
methadone
Detoxification
Maintenance
Induction to
buprenorphine
Dependent
methadone user
Dependent
heroin user
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8. Maintenance buprenorphine
prescribing (see also the Clinical Guidelines1)
The value of substitute maintenance prescribing for opioid
dependency is well established, in which buprenorphine
has a place9 10. The dose range of buprenorphine
maintenance prescribing is 8 to 32 mg daily. The most
usual range used to achieve abstinence from heroin use
is between 12 to 24 mg daily. As a partial agonist, higher
doses of buprenorphine may not produce corresponding
increases in effects, so increasing the dose may not
make any difference in subjective effects (e.g. increased
euphoria), but may further reduce illicit opioid use by
increasing the blockade effect.
There should be regular reviews of treatment, including
care-plans and goals, which should be at least 3 monthly
and should include checking for injecting sites. The usual
General Medical Services should always be offered
(including blood borne virus screening, hepatitis
vaccinations [HBV and HAV if injector], smears, etc.).
Patients should be made aware of, and be able to access,
a range of social and psychological services within the
local environment.
Optimal outcomes with buprenorphine maintenance will
occur when a range of other non-pharmacological
interventions, such as counselling, support the prescribing
of buprenorphine19.
Frequency of dosing
 Buprenorphine should normally be prescribed on a
DAILY regimen.
 It has the potential of being able to be administered
every 2 to 3 days, although no more than 32 mg
should be dispensed in one day.
 Alternate day dispensing will have advantages for
supervised consumption (supervised self-administration),
as daily attendance at the pharmacy will not be necessary.
 Patients who have been stable on buprenorphine for
3 months, who have no high-risk drug use (e.g. ongoing
use of heroin, other injecting drug use, alcohol or
benzodiazepines, frequent intoxicated presentations,
recent history of overdose) and make this choice, may
be considered for reduced-frequency dosing.
 The effectiveness of alternate day dosing is somewhat
unclear and should only be considered after
consultation with an experienced  prescriber.
The following guide to dose levels can be
recommended:
2-day dispensing regimen: 2 x daily dose
(up to a maximum of 32 mg)
3-day dispensing regimen: 3 x daily dose
(up to a maximum of 32 mg)
The above conversion chart is a guide only, and the dose
should be titrated according to clinical need and response.
There are safety concerns (e.g. liver function) about
dosing clients with more than 32 mg on any given day,
and a specialist should be consulted prior to attempting
such high doses.
Some individuals (at least one third of patients) will not
tolerate 2-day or 3-day dispensing regimes because they
experience increased cravings or features of withdrawal
on the non-dosing days, and it will be necessary to
maintain them on a daily dispensing regime.
Instalment prescribing
Buprenorphine can be written using FP10 (MDA)
prescriptions (Instalment) in England (since 1999), in
Wales (since February 2003), and in Scotland using a
GP10 or GP10(SS)(3) where the prescriber has a Home
Office exemption from handwriting requirements.
Missed doses
Missed doses can be associated with the emergence of
an opioid withdrawal syndrome after 2 or 3 days. Patients
who have missed doses of buprenorphine should be
encouraged back into treatment. The prescribing doctor
should review patients who have missed more than
3 consecutive days of buprenorphine, and retitrate dose
levels up to an appropriate maintenance dose. If they
have gone back to illicit heroin then the titration needs
to be started again as option 1.
 Daily dispensing regimens
If a patient on a daily dispensing regimen misses a
pickup from the pharmacy, the patient should return
the next day as usual for their next dose. The missed
dose should not be replaced.
Patients who repeatedly miss doses should have their
treatment reviewed. If on less than daily dosing the first
step would be to revert to daily dispensing.
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Option 1:
Induction from heroin (can be undertaken in primary
care if doctor has necessary support and experience)
 The first dose of buprenorphine should be administered
at least 8 hours after the last use of heroin and preferably
with mild withdrawals present to reduce the risk of
precipitated withdrawal (see Box 4). Precipitated
withdrawal is rare with transfer from heroin7.
 A first dose of 4 mg buprenorphine is generally
recommended. Starting doses of between 4 mg
to 8 mg can be used and are safe subject to there
being no precautions (see Box 3).
 The dose can be increased by between 2 to 8 mg
daily, usually 4 mg, until the patient is stabilised, up
to a maximum of 32 mg / day. A common effective
dose is between 12 to 24 mg, though lower or higher
doses may be appropriate in some patients18.
Option 2:
Induction from methadone (can be undertaken in
primary care if doctor has necessary support and
experience)
 The dose of methadone should be reduced to and
stabilised on 30 mg or less.
 The first dose of buprenorphine should be administered
at least 24 to 36 hours after the last use of methadone
and preferably with mild to moderate withdrawals.
 Increasing the time interval between the last dose of
methadone and the first dose of buprenorphine reduces
the incidence and severity of precipitated withdrawal
(see Box 4).
 The principles for starting doses are shown in the
table below.
Last methadone Buprenorphine Buprenorphine
dose Day 1 Day 2
20 to 30 mg 4 mg 6 to 8 mg
10 to 20 mg 4 mg 4 to 6 mg
<10 mg 2 mg 2 to 6 mg
Subsequent titration procedures are the same as for
induction from heroin (see above).
Option 3:
Induction from methadone doses between 30 to
60 mg (should only be undertaken in intermediate or
specialist service and/or if the doctor has necessary
experience).
Starting buprenorphine from higher than 30 mg can be
conducted as follows:
 The methadone dose should be reduced as far as
possible without the patient becoming unstable or
chaotic, and then abruptly stopped.
 The first buprenorphine dose should be delayed until
the patient displays clear signs of withdrawal, which
is generally longer than 24 to 36 hours but may be as
long as 48 to 96 hours, after the last methadone dose.
Symptomatic medication, such as lofexidine, may be
useful to provide the patient with some transitory relief.
 An initial dose of 4 mg of buprenorphine should be
given and following this the patient should be reviewed
2 to 3 hours later.
 If withdrawal has been precipitated (see Box 4), further
symptomatic medication can be prescribed.
 If there has been no precipitation or worsening of
withdrawal, an additional 2 to 4 mg of buprenorphine
can be dispensed on the same day.
 The patient should be reviewed the following day at
which point the dose should be increased to between
8 to 12 mg. Thereafter, titration should be effected
as for heroin induction (see above).
Option 4:
Induction from levels of methadone greater than
60 mg daily should not be attempted in primary care.
 If a patient is on more than 60 mg of methadone and
wants to change to buprenorphine then they should
be referred to the local specialist drug service.
7. Stabilisation of buprenorphine dose
Stabilisation involves finding a suitable dose that keeps
the patient engaged in treatment without the need to
supplement with other drugs and use heroin ‘on top.’
Dose stabilisation may take several days. It is important
that this is achieved as quickly as possible to prevent
patient drop out. To this effect, the dose of buprenorphine
should be increased daily until the dose is stable, such
that the patient does not experience withdrawal symptoms.
Sleep difficulties must be taken seriously and advice
about sleep hygiene should be given. Consider a short-
term (less than 5 days) prescription of diazepam to help
the initial sleep difficulties while stabilising.
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 HIV medications:
There is no known interaction with HIV combination
therapies. As with other opioids, patients being treated
with HIV combination therapies may require
buprenorphine dose levels to be adjusted. These
adjustments are likely to be minor and, in keeping with
titration principles, sufficient to ensure patient comfort23.
It is advisable to offer substitute prescribing treatment
in conjunction with an HIV specialist.
 Hepatitis C (HCV) medications:
There is good data on interferon / ribavirin and
methadone showing that there are no problems.
It is likely to be similar with anti-HCV therapy and
buprenorphine but further research and experience
is required.
Addressing continued heroin
and other drug use
Some patients may find it difficult to stabilise and be
maintained on buprenorphine. This may be evident by:
 Urine screens repeatedly positive (more than twice)
for heroin or methadone
 Concurrent use of other drugs (such as alcohol, illicit
benzodiazepines, cocaine or amphetamines)
 Clinical evidence of continued opioid use, such as
fresh injecting sites, pin-point pupils
 Overdoses and / or presentations to A & E,
out of hours, etc
 Frequent missed doses
 Physical or mental deterioration due to continued
drug use
This requires a review of treatment, the first step being
to determine that the patient is taking the medication
properly7. If the patient is taking more than 2 tablets at
one time and is finding this uncomfortable, advise them
to take no more than 2 at any one time and allow all to
dissolve in the mouth, checking the dose is sufficient
and increasing as necessary. This uncomfortable feeling
usually occurs early in treatment. Later in treatment it
may be due to the development of tolerance, which
although not common with buprenorphine, can occur.
As with other treatments, it is important to check the
patient is receiving appropriate psychosocial interventions.
Always check all factors before withdrawing from
maintenance treatment or transferring to alternative
pharmacotherapies (e.g. methadone).
9. Buprenorphine and liver disease
Buprenorphine is metabolised by the liver and the activity
of buprenorphine may be increased and / or extended in
individuals with impaired hepatic function7.
 Buprenorphine appears safe in patients with
hepatitis C infection (HCV) as long as the patient has
normal liver function and no evidence of cirrhosis.
 There have however been reports of deterioration in
liver function in those with pre-existing liver disease
(e.g. HCV or HBV) and who inject their buprenorphine
tablets or take an overdose of buprenorphine,
so caution should be exercised24.
In practice it is recommended that:
 LFTs are checked at assessment, but waiting for the
results should not delay the starting of buprenorphine
if the patient is well.
 If LFTs are normal, monitor periodically (e.g. 6 monthly)
through treatment as buprenorphine can cause an
increase in aspartate aminotransferase (AST) and
alanine aminotransferase (ALT).
 If there is evidence of liver disease (e.g. HCV antibody
positive, alcohol misuse), take LFTs before commencing
buprenorphine treatment (baseline) and monitor LFTs
again after 2 to 3 months.
 If there is evidence of marked deterioration in LFTs,
refer to a liver specialist for advice.
Buprenorphine and kidney disease
There is no significant difference in the kinetics of
buprenorphine when patients with renal failure or renal
impairment are compared to controls7.
10. Detoxification from buprenorphine
stabilisation or maintenance
Buprenorphine is a useful detoxification agent in both
primary care and specialist settings25. Detoxification
regimens should always be undertaken with the patient’s
full agreement (not forced) and be tailored to meet the
needs of the patient. It is important to clarify treatment
aims with the patient (e.g. expectations, concerns, and
aftercare / support needs) at the outset.
Reduction can be slowed or stopped if the patient
experiences difficulties or there is a resumption of heroin
or other drug use, as is often seen when detoxifying from
any opioid e.g. methadone.
Most patients do not experience significant withdrawal
discomfort until they have reduced to low doses of
buprenorphine, or even until after doses have stopped.
The withdrawal syndrome is worse after buprenorphine
treatment of six months or longer.
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Supervised consumption
(supervised self-administration)
and take-home doses
There are benefits and problems associated with take-
home doses. Benefits include the practical and
psychological advantages of greater patient control.
Problems include the possibility of poor compliance,
injection of tablets and diversion onto the illicit market.
Supervised consumption (if available) should be continued,
where possible, until the prescriber is satisfied that the
patient has been stabilised on the correct dose and
maintains a reasonable level of compliance. For the
pharmacist to be able to provide supervision, the tablet/s
should be administered sublingually and the patient
supervised until the tablets have dissolved (5 minutes or
more). In many areas, pharmacists are paid for providing
this supervision.
Some pharmacists may be prepared to crush
buprenorphine tablets, if requested by the prescribing
doctor, as a means of reducing the time required for
supervision and minimising risks of diversion of medication.
Buprenorphine is not currently licensed to be
administered like this and there may be problems with
product liability. Crushed tablets become unlicensed
products for which the manufacturer is no longer liable
for any damage caused to the patient. Prescribers
and / or pharmacists should contact their local Primary
Care Organisation or Mental Health Trust to determine
the local policy and confirm with their insurer that they
have the necessary professional indemnity cover.
Once the patient is sufficiently stable, less frequent
dispensing or take home doses can be given. If giving
take home doses, it may help to gradually change the
frequency of pick up, to three times weekly, twice weekly
and then weekly, assessing stability at each stage. It is
not appropriate to arrange for buprenorphine to be
dispensed less frequently than weekly.
Urine testing
Buprenorphine is not detected in routine tests for opioids.
Some laboratories are able to test for buprenorphine by
special arrangement (using microplate urine tests and / or
oral fluid testing). In most circumstances, urine testing
to confirm diagnosis of opiate use would be undertaken
before commencement of substitute treatment with
buprenorphine. The frequency of urine testing thereafter
depends on clinical progress1 but this should be no less
frequently than bi-annually.
Overdose
As buprenorphine is a partial opiate antagonist it is safer
in overdose than full agonists, such as methadone,
causing less respiratory depression17 20. There is less
risk of overdose in opioid-naïve individuals. However, the
phenomenon of opioid related death is complex and
buprenorphine related deaths have been reported in
combination with other sedative drugs such as alcohol
or benzodiazepines, but less than with methadone21 22.
As buprenorphine is not easily displaced by the antagonist
naloxone, high doses (10 to 30 times the normal naloxone
doses used to reverse opioid overdose) are needed to
reverse effects of buprenorphine and may be of limited
value. The initial management of overdose involves basic
principles of maintaining respiration and circulation and
referral to appropriate emergency services.
Drug interactions
(see also Box 3: Precautions)
The main drug interactions of buprenorphine are due to
its opioid activity.
 Benzodiazepines:
Many drug users also use benzodiazepines and deaths
have been known to occur as a result of the combination
of buprenorphine with benzodiazepines and / or
alcohol22. As with other opiate substitute treatments,
caution is advised and review procedures are
recommended when prescribing benzodiazepines1.
 Alcohol, other sedatives, anti-depressants:
Alcohol intake may impair the metabolism of
buprenorphine. Mixing buprenorphine with alcohol or
other CNS depressants can be dangerous. Caution
is advised, as are thorough assessment and review
procedures. Some anti-depressants including tricyclic
antidepressants and monoamine oxidase inhibitors
(MAOIs) should be prescribed with caution due to
possible sedation.
 Cocaine:
There are no reports of a significant interaction with
cocaine. This is likely to be due to cocaine being
metabolised by different enzymes.
 Other full opioid agonists (e.g. opiate analgesia):
Buprenorphine may precipitate opioid withdrawal
syndrome when given to those taking full opioid
agonists (e.g. morphine). Buprenorphine reduces the
effects of other opioids given for analgesia.
 Opioid antagonists:
Delayed opioid withdrawal syndrome can be
precipitated by the use of naltrexone.
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15. Buprenorphine,
Misuse of Drugs Act 1971
Buprenorphine is defined by the Misuse of Drugs Act
1971 as a Class C drug and falls within Schedule 3
(as compared to methadone which falls within Schedule 2)
of the Misuse of Drugs Regulations 2001.
NB: Schedule 2 drugs are subject to the full controlled
drug requirements relating to prescriptions, safe custody,
the need to keep registers, etc.
Schedule 3 drugs are subject to the special prescription
requirements and some are exempt from the safe custody
requirements. However, buprenorphine (and temazepam)
must be kept in a CD cabinet and there is a requirement
to keep registers (although there are requirements for
the retention of invoices for 2 years).
16. Injecting buprenorphine
and the potential for misuse
The misuse of buprenorphine and the injecting of tablets
has been recognised for a number of years. In the early
1990’s low dose tablets of buprenorphine (known as
Temgesic®) were injected by drug users in a number of
areas (e.g. Glasgow and Edinburgh) and since then there
have been a number of reports from around the world
showing often high risks of injecting these tablets, which
like all formulations of buprenorphine, are highly soluble.
More recent information from France on the use of higher
dose tablets of buprenorphine showed suspected
intravenous use of the tablets in 10 to 15% of cases
and irregular use in as many as 20 to 30% of patients.
Similar high rates of injecting buprenorphine tablets are
emerging from Australia. It is unknown how much of the
drug is diverted in the UK but supervised consumption
may help reduce diversion.
17. Cost
The cost of the drug buprenorphine is more expensive
than methadone.
Buprenorphine: 2 mg, 7-tab pack = £6.72
8 mg, 7-tab pack = £20.16
Methadone mixture
1 mg / ml: 100 ml = £1.45
500 ml = £7.59
Source: British National Formulary, 47, March 2004
As buprenorphine is a schedule 3 drug it consequently
attracts a lower dispensing fee than methadone.
In a recent study, treatment with methadone was found
to be less expensive and more effective than treatment
with buprenorphine, but when the costs that were relevant
to the provision of treatment were included (e.g. staff
costs), the cost-effectiveness differences between
buprenorphine and methadone were not statistically
significant 14.
18. Further reading
Pharmacy Guidance on the use of buprenorphine National
Pharmaceutical Association. Edited by Martin Bennett,
Sonia Garner, Anshu Hinton and Michelle Styles
(March 2004).
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A gradual dose reduction schedule is proposed as follows:
Daily buprenorphine Reduction
dose rate
Above 16 mg 4 mg every 1 to 2 weeks
8 to 16 mg 2 to 4 mg every 1 to 2 weeks
2 to 8 mg 2 mg every 1 to 2 weeks
Below 2 mg 0.4 to 0.8 mg every 1 to 2 weeks
Patients may prefer to reduce more slowly than this.
Alternatively, more rapid dose reductions may be
considered (for example, if the patient has had a brief
period of heroin use, or has a limited time period to
complete withdrawal [e.g. facing a prison sentence]).
Rapid dose reductions to zero have been achieved within
a one-week timeframe in people withdrawing from heroin,
but are not usually recommended in outpatient settings
without considerable psychosocial support.
Transferring from buprenorphine to naltrexone
after detoxification
Naltrexone can be useful in some patients to prevent
relapse after detoxification from opioids.
The speed at which naltrexone can be initiated depends
both on the final dose level of the buprenorphine, and
on how tolerant of potential precipitated withdrawal the
patient is prepared to be. Thus the initiation period may
range between 48 hours and 7 days.
Non-pharmacotherapeutic options
It is important that the patient’s needs following
buprenorphine detoxification have been assessed and
considered as part of the care planning process. There
is a range of non-pharmacological options that may help
prevent relapse. These include access to counselling
and support, day care, employment and training projects,
AA/NA groups, self-help and advocacy groups, and
residential rehabilitation facilities. Local drug services will
have information about the availability of these options
and how they can be accessed.
11. Transfer to methadone 
maintenance treatment
Some patients may need to transfer from buprenorphine
to methadone. Possible reasons include: intolerable side
effects; an inadequate treatment response; the lack of
availability of buprenorphine in an area into which a patient
has moved; and complications around the interaction of
other drugs such as opiate agonists e.g. patients requiring
frequent opioid analgesia for recurrent pain.
If a patient is stable on buprenorphine, methadone can
be commenced 24 hours after the last dose, at an initial
daily dose of up to 40 mg. Appropriate dosage levels
vary according to the dose of buprenorphine and individual
factors. The following table gives guidance but dose
levels of methadone should be titrated according to the
response (being mindful of the residual blockading effect
of buprenorphine which may last for a number of days
and the long half-life of methadone):
Dose levels (guide only)
Buprenorphine dose Methadone dose
>8 mg 40 mg
4 mg 20 mg
2 mg 10 mg
12. Shared care
Maintenance prescribing of buprenorphine and
detoxification interventions should be undertaken in a
planned manner in collaboration with the patient and any
carers. Shared care arrangements are increasingly an
important feature of local treatment arrangements and
GPs should endeavour to work jointly with drug workers
from local drug services or shared care schemes,
where appropriate.
13. Patient education
The particular and different properties of buprenorphine
compared to full opioid agonists such as methadone
mean that it is important that patients are given good
information about its action and effects. This should
include information on the method of self-administration
(sublingually and not swallowed), effects and unwanted
effects, how to start, and the risk of potentiation if used
with other sedative substances such as benzodiazepines
and alcohol.
Consideration should be given to providing patients with
written as well as verbal information about treatment issues.
Appendix 1 is a leaflet that can be photocopied and
given to patients.
14. Training
Practitioners should only prescribe and treat at levels of
practice with which they feel competent and for which
they have received adequate training. There may be local
or regional training opportunities around buprenorphine
that can be accessed by GPs, pharmacists, and other
members of the primary health care team.
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 What is buprenorphine?
Buprenorphine is the general name given to the
medication you have been prescribed. The
manufacturer’s name for buprenorphine in this country
is Subutex, and you may hear your medication
called this. You may have been started straight from
heroin, or transferred from methadone. Either is possible.
Buprenorphine is an opioid drug. It produces a
depressant effect on your system, similar (though not
identical) to heroin or methadone, which are also
opioids. Buprenorphine can block the effect of heroin
or methadone if you use ‘on top’, helping you to
reduce your use of street drugs.
 Why buprenorphine?
Buprenorphine is a licensed alternative to methadone,
which has some possible advantages for some people.
One of them is that it is probably less dangerous if
you overdose and another is that it gives you a clearer
head. Also, people tend to find it easier to come-off
(known as reduction or detoxification). It may not be
the best choice if your heroin or methadone habit
is large.
 How do I take buprenorphine?
Buprenorphine comes in tablet form and it only has
an effect when it is dissolved under the tongue (also
called sublingually). If you swallow or chew your tablets
they will not work as the stomach juices destroy them.
You may be left with a pool of saliva in your mouth
but it is OK to swallow this after the tablet has all
dissolved. Buprenorphine tablets take between
3 and 5 minutes to dissolve under the tongue.
Allowing buprenorphine to dissolve under the tongue
may feel different, especially if you are used to
taking your drugs by smoking, injecting or by
swallowing. You should try and take your tablets
as one single dose at the same time each day.
This will help stabilise your body.
 Why do I need to wait after taking heroin or
methadone before taking buprenorphine?
You will be asked to wait for at least 8 hours after last
taking heroin and between 24 to 36 hours after last
taking methadone (even if not prescribed) before
taking your first dose of buprenorphine. It will also be
necessary to lower your methadone dose (to around
30 mg / day) before starting buprenorphine. This is
because you need to get most of the heroin or
methadone out of your system before buprenorphine
can have a positive effect. If you take buprenorphine
too soon, you may put yourself into withdrawal. It is
best to wait as long as you can, ideally until you start
to feel the first signs of withdrawal.
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Appendix 1: Please photocopy and give to your patient
Buprenorphine in primary care:
Patient information – update 2004
Important Points
 You need to take your first dose of buprenorphine when you have no methadone
or heroin in your system, or it will make you withdraw.
 Let your buprenorphine dissolve under the tongue. It doesn’t work if you swallow it.
 If you want to continue using heroin then buprenorphine is not the drug for you.
 Trying to overcome the block by using increased amounts of heroin ‘on top’ puts you
at risk of overdose.
You have been prescribed buprenorphine by your general practitioner (GP) or prescriber. This leaflet aims to
give you some information about the drug and how it can help you. There are patient booklets that cover this
in more detail, so ask your GP or drug worker if they can provide you with one. A booklet is no substitute for
talking to your doctor, nurse, drug worker or pharmacist – so, if there is something you need more information
about, just ask. They will be happy to try and answer your questions and if they can’t answer your question
they may know someone who can.
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Advantages of buprenorphine compared to
methadone:
1. Less dangerous in overdose
2. With maintenance doses between 8 to 32 mg the
effects of other opioids used ‘on top’ are markedly
reduced (maximal effect between 12 to 24 mg daily)
3. Useful in maintenance and detoxification
(reported as easier to withdraw from)
4. Clearer head whilst on medication, less ‘clouding’ effect
Disadvantages of buprenorphine:
1. Highly soluble leading to potential for injection
2. Can precipitate acute opiate withdrawal if used incorrectly
3. Less ‘opiate-like’ or ‘clouding’ effect
4. The drug itself is more expensive than methadone
5. May be less effective at retaining people in treatment
Starting buprenorphine
 Carried out by dose induction in a similar way to
methadone induction, but this can, and should, be
undertaken much more rapidly (i.e. over a few days)
to reduce drop out.
 Generally advised to start at 4 mg a day and increase
by between 2 to 8 mg (usually 4 mg) daily until stabilised,
to a maximum of 32 mg per day. Commonly achieve
stability between 12 to 24 mg.
 Initiate buprenorphine at least 8 hours after the last
dose of heroin, and between 24 to 36 hours after the
last dose of methadone (so the previously taken
opiates have been metabolised) and with the first
signs of withdrawal, to prevent precipitated withdrawal.
 Ask the patient to wait as long as possible, so the
previously taken opiates have been metabolised before
taking the first dose, to help the induction.
 Always give full explanation of the drug and its
effects to the patient.
 Explain that for the first 3 days the patient may
experience some unpleasant effects such as headache,
restlessness, insomnia and diarrhoea. Lofexidine may
be helpful with these unpleasant effects.
 Those on more than 30 mg methadone per day will
need to reduce to 30 mg or be transferred to a specialist
for conversion to buprenorphine.
 The value of substitute maintenance prescribing for
opioid dependency is well established, in which
buprenorphine has a place. The dose range of
buprenorphine maintenance prescribing is 8 to 32 mg
daily. The most usual range used to achieve abstinence
from heroin use is between 12 to 24 mg daily.
 Buprenorphine detoxification may be carried out using
rapid or gradual regimes according to the needs of
the patient.
 Installment prescribing can be written on an FP10
(MDA) in England and Wales, or a GP10 in Scotland
Buprenorphine is a useful alternative substitute
medication for opioid dependent people. It widens
the choice for opiate users who do not want methadone
or who are intolerant to it. It is a useful addition for
substitute medication. It is not appropriate if the patient
is stabilised and doing well on methadone. It may be
considered as a first choice for people dependent on
opioids who wish to become opiate free.
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 How will buprenorphine make me feel?
The maximum effect of buprenorphine can take over
an hour to feel. The high that you get while you are
taking buprenorphine is not as strong as the high you
felt when you were using heroin or even methadone,
but you will not go into withdrawal. It can feel quite
different and you might find that this can take a bit of
getting used to. However, after a few days of
buprenorphine, you should feel less and less craving
for heroin, and feel more ‘in control’, more ‘clear-
headed’ and more alert, in contrast to the ‘clouding’
effect of heroin or methadone. For some people this
is a bonus, others don’t like it. If you are going for
maintenance you may want to think about this when
making your choice.
 Will I have to take my dose in front of the pharmacist?
Taking medication at the chemist in front of a
pharmacist is called supervised consumption.
Most people will have to undergo supervised
consumption to start with as it is considered to
be the best way of ensuring you are taking your
buprenorphine safely and correctly. If you can show
your doctor that you are stabilised on buprenorphine
(i.e. you are not using heroin or other drugs bought
illicitly) over a period of weeks or months (the
government recommendation is 12 weeks unless
there are good reasons such as working or child care
for it to be less), there is no reason why you should
not ask to have take-home doses of buprenorphine.
Ultimately however, this is a decision that only your
GP or prescriber can make.
 What should I do to keep other people and
myself safe?
Though buprenorphine is relatively safe there are
dangers involved in taking any opiate-like drug in
large quantities when one is not used to it. The risks
are greater if buprenorphine is taken in combination
with other depressant drugs. This is particularly true
of drugs called benzodiazepines (‘benzos’ such as
diazepam [Valium], temazepam, Mogadon, or
Rohypnol) that are commonly prescribed for sleeping,
stress or anxiety problems. However, it is also true
of some other drugs that are sometimes prescribed
by doctors e.g. antidepressants. Please tell your GP
if you are taking any other drugs or prescribed
medication.
People often forget that alcohol is a drug too.
Like benzodiazepines and the other drugs mentioned,
alcohol can be dangerous when taken with
buprenorphine. So, if you do have a drink, be very
careful not to overdo it. You should not drink more
than 3 units (one and half pints of beer or 3 glasses
of wine) for a man or more than 2 units for a woman
per day.
Because opiates can harm and even kill people who
are not used to taking them, it is important that no
one else takes or gets access to your medication.
Like all medicines, but especially with these drugs,
it is very important that buprenorphine is stored
safely out of the reach of children.
 What will happen if I use heroin ‘on top’?
Buprenorphine reduces the effect of heroin for a long
time, making it more difficult for you to get a ‘buzz.’
If you use a lot of heroin you are no more likely to get
a buzz, but you run the risk of overdosing as the
buprenorphine begins to wear off.
 What will happen if I inject buprenorphine?
Buprenorphine should not be injected and can be
painful if it is. It can also cause tissue and vein
damage leading to circulation problems. Damaged
tissue can allow infection in more easily and can result
in abscesses and cellulitis. If you have liver problems
from hepatitis C or alcohol injecting can, in some
people, cause deterioration in your liver function.
If you inject and share any of your injecting equipment,
you run the risk of catching a blood borne virus
infection like HIV or hepatitis C. Your injecting sites
will be checked periodically and if you are found to
be injecting buprenorphine this could lead to your 
script being witheld (for your own safety).
 What happens if I get pregnant while on
buprenorphine?
At the present time little is known about the safety of
buprenorphine for the baby during pregnancy.
This does not mean it cannot be used or is dangerous,
just that the doctor needs to explain the risks and
benefits to you. Talk to your GP, prescriber or primary
care team member as soon as you find out that you
are pregnant, and they will give you the best advice
about what your options are. The best choice may
be to continue. Don’t stop your buprenorphine without
discussing it first.
 What happens if I am planning a pregnancy when
entering treatment?
If you are planning a pregnancy you should inform
your GP or prescriber as this may influence whether
or not buprenorphine is the best medication for you.
 Can I drive on buprenorphine?
You need to inform the DLVA that you are receiving
a prescription of buprenorphine (as you do with
methadone). You can then drive for personal reasons
(not for work) while taking buprenorphine having
undergone a short independent medical examination,
which will include a urine screen for drugs. The licence
will be issued for one year at a time and will need to
be supported by a favourable medical report from
your doctor. It is your responsibility to do this, not the
doctor or the drug worker. If you do not notify the
DVLA and drive and get stopped by the police,
you will compromise your insurance and you could
be heavily fined or sent to jail.
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What is it, how to start it and how to use it
 Buprenorphine (Subutex) can be a useful addition to the formulary of medications for treating opioid dependence
either for maintenance or detoxification purposes.
 Because of its safety profile, low abuse potential and clinical flexibility in use, it is well suited to use in primary care.
 It comes in 8 mg, 2 mg and 0.4 mg (400 mcg) tablets, which need to be taken sub-lingually
(dissolved under tongue) as swallowing inactivates the drug properties.
 It is most suitable for use in primary care for those patients who are opioid dependent and are on either heroin
or 30 mg or less of methadone (or can reduce to this level)
 Direct equivalence between buprenorphine and methadone is difficult to estimate and is not a linear relationship,
12 to 16 mg buprenorphine is approximately as effective as 50 to 80 mg methadone in reducing heroin use and
retaining patients in treatment.
 Like methadone, buprenorphine interacts with other central nervous system depressants including benzodiazepines,
antidepressants and alcohol.
